MX2023011498A - Toallita topica que contiene nifedipina y lidocaina. - Google Patents

Toallita topica que contiene nifedipina y lidocaina.

Info

Publication number
MX2023011498A
MX2023011498A MX2023011498A MX2023011498A MX2023011498A MX 2023011498 A MX2023011498 A MX 2023011498A MX 2023011498 A MX2023011498 A MX 2023011498A MX 2023011498 A MX2023011498 A MX 2023011498A MX 2023011498 A MX2023011498 A MX 2023011498A
Authority
MX
Mexico
Prior art keywords
lidocaine
wipes containing
containing nifedipine
nifedipine
topical
Prior art date
Application number
MX2023011498A
Other languages
English (en)
Spanish (es)
Inventor
Robbie Schwenker
Matthew Stahl
Original Assignee
Steel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Steel Therapeutics Inc filed Critical Steel Therapeutics Inc
Publication of MX2023011498A publication Critical patent/MX2023011498A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2023011498A 2021-04-01 2022-04-01 Toallita topica que contiene nifedipina y lidocaina. MX2023011498A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163169768P 2021-04-01 2021-04-01
PCT/US2022/023130 WO2022212892A1 (en) 2021-04-01 2022-04-01 Topical wipe containing nifedipine and lidocaine

Publications (1)

Publication Number Publication Date
MX2023011498A true MX2023011498A (es) 2024-01-17

Family

ID=83456873

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011498A MX2023011498A (es) 2021-04-01 2022-04-01 Toallita topica que contiene nifedipina y lidocaina.

Country Status (8)

Country Link
US (1) US20240156756A1 (cg-RX-API-DMAC7.html)
EP (1) EP4312984A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024512791A (cg-RX-API-DMAC7.html)
CN (1) CN117377461A (cg-RX-API-DMAC7.html)
AU (1) AU2022252406A1 (cg-RX-API-DMAC7.html)
CA (1) CA3213764A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023011498A (cg-RX-API-DMAC7.html)
WO (1) WO2022212892A1 (cg-RX-API-DMAC7.html)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04124128A (ja) * 1990-09-13 1992-04-24 Lion Corp 肛門部疾患治療用貼付剤
JP3012732U (ja) * 1994-12-20 1995-06-27 茂郎 槇島 痔治療の薬剤保持部材
IT1297886B1 (it) * 1997-02-28 1999-12-20 Carmine Antropoli Nifedipina per uso topico
JP2001170159A (ja) * 1999-12-19 2001-06-26 Alcare Co Ltd 緩衝能を有する接皮部材
US20040167479A1 (en) * 2003-02-20 2004-08-26 The Procter & Gamble Company Hemorrhoid treatment pad
US8377459B2 (en) * 2003-07-09 2013-02-19 The Procter & Gamble Company Composition for wet wipes that enhances the efficacy of cleansing while being gentle to the skin
WO2014140925A2 (en) * 2013-03-10 2014-09-18 Peritech Pharma Ltd. Topical compositions and methods of treatment of topical disorders
PT3220924T (pt) * 2014-11-17 2022-01-12 Rev Pharma Corp Medicamento tópico para lesões da pele e mucosas associadas à epidermólise bolhosa
WO2016118040A1 (ru) * 2015-01-21 2016-07-28 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" Гель, содержащий нифедипин и лидокаина гидрохлорид, его применение и способ приготовления с использованием нанотехнологий
IT201800002413A1 (it) * 2018-02-05 2019-08-05 Carmine Antropoli "composizione a base di nifedipina per uso nel trattamento delle ragadi anali e proctalgie"
BR102018008324A2 (pt) * 2018-04-25 2019-11-05 Laboratórios Ferring Ltda. composição farmacêutica de uso tópico e processo de fabricação de composição farmacêutica de uso tópico
EA036752B1 (ru) * 2019-02-25 2020-12-16 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" Способ получения геля для ректального и наружного применения, включающего нифедипин и лидокаина гидрохлорид (варианты)

Also Published As

Publication number Publication date
EP4312984A1 (en) 2024-02-07
US20240156756A1 (en) 2024-05-16
WO2022212892A1 (en) 2022-10-06
EP4312984A4 (en) 2025-02-19
CN117377461A (zh) 2024-01-09
AU2022252406A1 (en) 2023-11-02
CA3213764A1 (en) 2022-10-06
WO2022212892A8 (en) 2023-11-16
JP2024512791A (ja) 2024-03-19

Similar Documents

Publication Publication Date Title
CL2020000075A1 (es) Carboxamidas como moduladores de los canales de sodio.
JOP20230073A1 (ar) بنزاميدات مستبدلة مع 3،1- ثيازول-2- يل
CO2022010098A2 (es) Inhibidores de proteínas kras mutantes
CO2020014217A2 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
MX2021010753A (es) Composiciones y métodos de uso que comprenden sustancias con acciones de plasticidad neural administradas a dosificaciones y formulaciones no psicodélicas/psicotomiméticas.
CL2020001349A1 (es) Compuestos, composición y uso de los mismos como moduladores de la expresión de pcsk9. (divisional solicitud 201902574)
CO2020001244A2 (es) Derivados de quinolina para tratar infecciones con helmintos
CO2018010966A2 (es) Nuevos derivados de pirazolopirimidina
MX2020006664A (es) Composiciones liquidas de suministro.
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
BR112015018087A8 (pt) composto, composição farmacêutica e uso
EP2513343A4 (en) METHOD AND COMPOSITIONS FOR TREATING SKIN INFLAMMATION
CL2009001215A1 (es) Composiciones farmaceuticas que comprenden un primer agente seleccionado del grupo consistente de i) un agente antiinflamatorio, ii) acetaminofeno, iii) fenacetina, iv) tramadol, y un segundo agente; uso de dichas composiciones para tratar enfermedades proliferativas incluyendo cancer.
DOP2016000253A (es) Nuevos compuestos
CL2021002574A1 (es) Composición farmacéutica acuosa de anticuerpo anti-il17a y su uso
MX2022008479A (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
CL2017002214A1 (es) Formulación de combinación de tesofensina y betabloqueante
CL2011003327A1 (es) Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
MX386732B (es) Composición farmacéutica de corticosteroide soluble.
CL2022001353A1 (es) Inhibidores de egfr
MX2023006235A (es) Composiciones para administracion de farmacos y metodos de uso de las mismas.
UY39569A (es) N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)- quinolin-4-carboxamidas